Nevertheless, CD27 agonistic antibodies exhibit anti-tumour functionality in both pre-clinical in vitro and in vivo models by enhancing CD27-mediated ICS and depletion of Tregs via ADCC (164, 165). Here, CD27 is linked to neoplasm.